Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

A patient shares how an event about clinical trials at Moores Cancer Center brought a community together to educate and ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Shares of Liminatus Pharma rose after the company shared plans to collaborate on developing a diagnostic kit for detecting pancreatic cancer. The stock advanced 3.7%, to $9.35, in after-hours trading ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion ...

Each year, it is estimated more than 40,000 people will be diagnosed with liver cancer – and those numbers are increasing.